Who may participate
This study is seeking healthy male participants, meaning that the participants will not have the condition being studied.
In addition to the criteria listed, participants must meet the following requirements:
- Weight of 50 kg minimum
- Body Mass Index of 17.5 - 30.5 kg/m2
- Non-smoker, ex-smoker, smoker (max 5 cigarettes per day)
- Able to meet all study visit requirements There are other requirements for participation in this study. The study staff will explain these to you during the screening process.
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can fully determine if you qualify to enroll in the study.
What to expect
For participants in Cohorts 7 to 12 the study is planned to last for approximately 19 weeks and includes:
• A selection examination, during which you will sign a COVID ICD and the study ICD;
• 1 treatment period of 10 days and 9 nights in the PCRU (from Day -2 to Day 8);
• 7 outpatient visits, occurring approximately 11, 15, 22, 29, 36, 50 and 71 days after the administration of the drug.
We may ask you to return to the PCRU for one additional outpatient visit after your last visit on Day 71 to collect blood samples for immunogenicity and safety assessments.
You will not personally derive any benefit from your participation in this study, but the results obtained could be very important for the development of medicines and treatments which will benefit other people.
€ 3005 upon completion of the study, + € 270 for COVID-19 inconvenience fees + transportation fees
Interested in participating?
New to clinical research? If you’re interested in becoming a participant or need more information on the registration process, please complete and submit the registration form. We will contact you as soon as possible
Already in our database? If you’d like to subscribe for this study, please contact us by phone.
Studies (recruiters) For more information, call 0800/99.256 (from abroad: 0032/2. 556.70.02 or 00800/2636.2636 from France, The Netherlands, Germany, UK) or email us.
Personal data means any information relating to you as a natural person such as for example your name, your date of birth, your telephone number or information relating to your health or your medical condition.
The personal data you share with us when completing the registration form is collected by the Brussels PCRU in order to send you the relevant literature and the medical questionnaire. It will be processed in a strictly confidential manner and in conformity with all applicable legislations, especially the European and Belgian laws applicable to clinical trials, and the European and Belgian laws applicable to personal data protection.
Personal data protection is very important to our clinical research unit. That’s why we ask that you read our Privacy Notice available at https://privacycenter.pfizer.com/en/belgium.